The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

While they have been around for some years, ADCs – which pair antibodies with a drug payload designed to boost their efficacy – are gathering momentum in biopharma drug development as early ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

Taiho Pharmaceutical Co., Ltd., an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases, and Araris Biotech AG, a Swiss biotechnology company developing ...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to $1.14bn, representing another big-dollar deal for the promising cancer ...

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload ...

The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating ...

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform. The two companies have been working ...

MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study in prostate cancer. The Rockville, Maryland-based biotech said trials of ...

Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates ...